Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

被引:19
|
作者
Jung, Yoon Yang [1 ]
Hyun, Chang Lim [2 ]
Jin, Min-Sun [3 ]
Park, In Ae [4 ]
Chung, Yul Ri [4 ]
Shim, Bobae [4 ]
Lee, Kyu Ho [4 ]
Ryu, Han Suk [4 ]
机构
[1] Myongji Hosp, Dept Pathol, Goyang, South Korea
[2] Jeju Natl Univ Hosp, Dept Pathol, Jeju, South Korea
[3] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Pathol, Bucheon, South Korea
[4] Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea
关键词
Core needle biopsy; Neoadjuvant therapy; Treatment outcome; Triple-negative breast neoplasms; LYMPH-NODE METASTASIS; PATHOLOGICAL COMPLETE RESPONSE; CORE NEEDLE-BIOPSY; PREOPERATIVE TREATMENT; RETRACTION ARTIFACT; FEATURES; DOXORUBICIN; EXPRESSION; CELLS; KI-67;
D O I
10.4048/jbc.2016.19.3.261
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. Methods: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled. The core needle biopsy specimens acquired before NAC were used to analyze the clinicopathologic variables and overall performance of the predictive model for therapeutic response. Results: Independent predictors of pathologic complete response after NAC were found to be higher number of tumor infiltrating lymphocytes (p=0.007), absence of clear cytoplasm (p= 0.008), low necrosis (p=0.018), and high histologic grade (p=0.039). In the receiver operating characteristics curve analysis, the area under curve for the combination of these four variables was 0.777. Conclusion: The present study demonstrated that a predictive model using the above four variables can predict therapeutic response to single-regimen NAC with the combination of doxorubicin, cyclophosphamide, and docetaxel in TNBC. Therefore, adding these morphologic variables to clinical and genomic signatures might enhance the ability to predict the therapeutic response to NAC in TNBC.
引用
收藏
页码:261 / 267
页数:7
相关论文
共 50 条
  • [1] Comment on "Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer" Reply
    Ryu, Han Suk
    [J]. JOURNAL OF BREAST CANCER, 2017, 20 (01) : 114 - 115
  • [2] Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
    du Terrail, Jean Ogier
    Leopold, Armand
    Joly, Clement
    Beguier, Constance
    Andreux, Mathieu
    Maussion, Charles
    Schmauch, Benoit
    Tramel, Eric W.
    Bendjebbar, Etienne
    Zaslavskiy, Mikhail
    Wainrib, Gilles
    Milder, Maud
    Gervasoni, Julie
    Guerin, Julien
    Durand, Thierry
    Livartowski, Alain
    Moutet, Kelvin
    Gautier, Clement
    Djafar, Inal
    Moisson, Anne-Laure
    Marini, Camille
    Galtier, Mathieu
    Balazard, Felix
    Dubois, Remy
    Moreira, Jeverson
    Simon, Antoine
    Drubay, Damien
    Lacroix-Triki, Magali
    Franchet, Camille
    Bataillon, Guillaume
    Heudel, Pierre-Etienne
    [J]. NATURE MEDICINE, 2023, 29 (1) : 135 - 146
  • [3] Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer
    Jean Ogier du Terrail
    Armand Leopold
    Clément Joly
    Constance Béguier
    Mathieu Andreux
    Charles Maussion
    Benoît Schmauch
    Eric W. Tramel
    Etienne Bendjebbar
    Mikhail Zaslavskiy
    Gilles Wainrib
    Maud Milder
    Julie Gervasoni
    Julien Guerin
    Thierry Durand
    Alain Livartowski
    Kelvin Moutet
    Clément Gautier
    Inal Djafar
    Anne-Laure Moisson
    Camille Marini
    Mathieu Galtier
    Félix Balazard
    Rémy Dubois
    Jeverson Moreira
    Antoine Simon
    Damien Drubay
    Magali Lacroix-Triki
    Camille Franchet
    Guillaume Bataillon
    Pierre-Etienne Heudel
    [J]. Nature Medicine, 2023, 29 : 135 - 146
  • [4] A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Chen, Xi
    Zhou, Zhiguo
    [J]. CANCER RESEARCH, 2024, 84 (03)
  • [5] Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
    Ding, Feng
    Chen, Ru-Yue
    Hou, Jun
    Guo, Jing
    Dong, Tian-Yi
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (12) : 3698 - 3708
  • [6] Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
    Feng Ding
    Ru-Yue Chen
    Jun Hou
    Jing Guo
    Tian-Yi Dong
    [J]. World Journal of Clinical Cases, 2022, 10 (12) : 3698 - 3708
  • [7] Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer
    van la Parra, R. F. D.
    Tadros, A. B.
    Checka, C. M.
    Rauch, G. M.
    Lucci, A., Jr.
    Smith, B. D.
    Krishnamurthy, S.
    Valero, V.
    Yang, W. T.
    Kuerer, H. M.
    [J]. BRITISH JOURNAL OF SURGERY, 2018, 105 (05) : 535 - 543
  • [8] Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer
    Kusama, Hiroki
    Kittaka, Nobuyoshi
    Soma, Ai
    Taniguchi, Azusa
    Kanaoka, Haruka
    Nakajima, Satomi
    Oyama, Yuri
    Seto, Yukiko
    Okuno, Jun
    Watanabe, Noriyuki
    Matsui, Saki
    Nishio, Minako
    Fujisawa, Fumie
    Honma, Keiichiro
    Tamaki, Yasuhiro
    Nakayama, Takahiro
    [J]. BREAST CANCER, 2023, 30 (06) : 1085 - 1093
  • [9] Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer
    Hiroki Kusama
    Nobuyoshi Kittaka
    Ai Soma
    Azusa Taniguchi
    Haruka Kanaoka
    Satomi Nakajima
    Yuri Oyama
    Yukiko Seto
    Jun Okuno
    Noriyuki Watanabe
    Saki Matsui
    Minako Nishio
    Fumie Fujisawa
    Keiichiro Honma
    Yasuhiro Tamaki
    Takahiro Nakayama
    [J]. Breast Cancer, 2023, 30 (6) : 1085 - 1093
  • [10] Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
    Mohamed Omar
    Pier Vitale Nuzzo
    Francesco Ravera
    Sara Bleve
    Giuseppe Nicolò Fanelli
    Claudio Zanettini
    Itzel Valencia
    Luigi Marchionni
    [J]. Journal of Translational Medicine, 21